- Home
- LLY
as 10-09-2025 3:45pm EST
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
| Founded: | 1876 | Country: | United States |
| Employees: | N/A | City: | INDIANAPOLIS |
| Market Cap: | 684.0B | IPO Year: | N/A |
| Target Price: | $969.56 | AVG Volume (30 days): | 4.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 15.29 | EPS Growth: | 88.31 |
| 52 Week Low/High: | $623.78 - $937.00 | Next Earning Date: | 10-30-2025 |
| Revenue: | $53,258,100,000 | Revenue Growth: | 36.83% |
| Revenue Growth (this year): | 38.34% | Revenue Growth (next year): | 18.38% |
Stock Insider Trading Activity of Eli Lilly and Company (LLY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| LILLY ENDOWMENT INC | LLY | 10% Owner | Oct 8 '25 | Sell | $852.10 | 101,420 | $86,234,873.84 | 94,547,580 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Oct 7 '25 | Sell | $848.01 | 26,795 | $22,722,401.16 | 94,547,580 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Oct 6 '25 | Sell | $852.07 | 161,183 | $137,041,656.51 | 94,547,580 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Oct 3 '25 | Sell | $834.94 | 192,404 | $161,220,401.35 | 94,547,580 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Oct 2 '25 | Sell | $826.99 | 112,596 | $92,503,361.30 | 94,547,580 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Oct 1 '25 | Sell | $804.45 | 351,015 | $284,653,464.64 | 94,547,580 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Sep 30 '25 | Sell | $764.75 | 113,694 | $86,793,273.90 | 94,547,580 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Sep 19 '25 | Sell | $763.76 | 23,665 | $18,058,643.25 | 94,547,580 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Sep 18 '25 | Sell | $765.38 | 106,626 | $81,531,958.91 | 94,547,580 | |
| Zakrowski Donald A | LLY | SVP, Finance, & CAO | Aug 28 '25 | Sell | $734.93 | 1,000 | $734,930.00 | 3,839.659 |
Latest Eli Lilly and Company News
LLY Breaking Stock News: Dive into LLY Ticker-Specific Updates for Smart Investing
Motley Fool
a day ago
Watch Out Eli Lilly, This Pharma Giant Is Gunning to Be a Top Player in the Obesity Market
MT Newswires
a day ago
Cantor Fitzgerald Adjusts PT on Eli Lilly and Co. to $925 From $825, Maintains Overweight Rating
Argus Research
a day ago
Daily – Vickers Top Buyers & Sellers for 10/09/2025
FreightWaves
2 days ago
Tariff turbulence deepens uncertainty across US supply chains
MT Newswires
2 days ago
Sector Update: Health Care Stocks Advance Late Afternoon
MT Newswires
2 days ago
Sector Update: Health Care Stocks Advance Wednesday Afternoon
Investor's Business Daily
2 days ago
Hims Stock, Up 138%: IBD Stock Of The Day Makes Another Breakout Run
Simply Wall St.
2 days ago
Is Eli Lilly’s Recent $1B India Investment a Game Changer for Its Valuation in 2025?
Compare LLY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LLY Eli Lilly and Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.